ALOX5 and asthma: ALOX5 inhibition can be associated with an improvement in asthma outcome, and it is known that the ALOX5 gene promoter has binding-sites for some transcription factors, including NF-κB. However, not all asthmatic patients will respond to antileukotrienes since those who have mutant alleles at the ALOX-5 should not have clinical benefits [84].